Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment

Table 2 Clinical Characteristics of 28 patients with chronic hepatitis B before and after long-term treatment of lamivudine

No.	Before treatment				After treatment				3Sequencing
	AST/ALT (IU/L)	HBeAg/anti-HBe	1HBV-DNA	2Nest-PCR	AST/ALT (IU/L)	HBeAg/anti-HBe	1HBV-DNA	Nest-PCR
1	61/62	-/+	39.93	-	29/16	-/+	0.25	V	V
2	31/43	+/-	3574.29	V	29/54	+/-	4400.65	M	V
3	85/86	-/+	348.66	-	20/11	-/+	0.20	-	W
4	45/90	-/+	8.50	-	23/22	-/+	0.03	-	W
5	74/75	-/+	256.99	I	63/38	-/+	0.01	I	I
6	82/163	-/+	1596.12	-	38/64	-/+	3356.38	V	V
7	37/43	+/-	13.07	-	25/39	+/-	0.26	-	W
8	26/62	-/+	49.16	-	24/40	-/+	0.03	-	W
9	82/102	-/+	3313.93	-	29/17	-/+	0.60	V	W
10	40/59	+/-	546.76	I	24/28	-/+	0.11	M	I
11	117/232	+/-	49.50	I	26/27	+/-	346.96	M	I
12	46/61	-/+	47.40	-	24/32	-/+	0.06	V	V
13	72/107	-/+	5.37	M	66/92	-/+	2389.09	M	V
14	155/159	+/-	2325.13	I	22/14	+/-	0.10	M	W
15	65/54	-/+	1461.13	-	42/29	-/+	0.12	V	W
16	133/157	+/-	7943.81	I	73/64	+/+	2.05	I	I
17	107/146	-/+	23.13	M	151/232	-/+	59.94	M	V
18	35/48	+/-	1666.59	-	22/21	+/-	0.15	-	W
19	247/183	+/-	9336.17	I	27/14	+/-	0.01	I	W
20	45/56	-/+	219.58	-	28/38	-/+	0.03	-	W
21	109/186	-/+	61.27	-	30/48	-/+	2.91	M	I
22	173/335	+/-	11.98	-	29/31	+/-	0.03	M	V
23	51/81	-/+	1403.11	I	28/42	-/+	303.09	I	I
24	43/68	+/-	365.07	-	22/27	+/-	1.28	V	V
25	45/57	+/-	7530.63	I	30/25	+/-	6228.83	I	I
26	130/286	-/+	126.67	-	21/32	-/+	1.46	I	I
27	64/91	+/-	4700.63	I	52/73	+/-	6.12	I	I
28	88/164	-/+	0.38	-	30/38	-/+	0.07	-	W

¹ Unit (10⁵copies/mL); ² M: YVDD + YIDD, V: YVDD, I: YIDD, -: YVDD and YIDD not detectable; ³ W: wild-type, V: YVDD, I: YIDD.